MDxHealth SA shares soared on Friday after the diagnostic company reported second-quarter revenue that beat expectations and reaffirmed its 2026 sales guidance, even as its quarterly loss came in wider than analysts expected. Revenue rose 16% year over year to $27.20 million, above the $25.884 million consensus, while the company posted a loss of 18 cents a share versus an expected loss of 16 cents. Gross profit increased 11% to $17.9 million. Tissue-based test volume for Confirm mdx and GPS mdx slipped 1% from a year earlier to 12,525 but rose 13% sequentially, while liquid-based Exo mdx volume reached 13,578 compared with Select mdx volume of 4,455 in the same period last year. MDxHealth said it completed the planned wind-down of Resolve UTI in the second quarter, including the permanent cessation of operations at wholly owned subsidiary Delta Laboratories and its Plano, Texas laboratory, as it refocuses on its core prostate cancer business. The company also said it eliminated a $10.4 million contingent liability to Novitas and raised $20 million through a registered direct financing, strengthening its balance sheet and cash position. Chief Executive Officer Michael McGarrity said tissue growth rates are expected to accelerate in the second half of the year, supporting a return to positive adjusted EBITDA as the company exits 2026. MDxHealth reaffirmed 2026 sales guidance of $110 million to $115 million, above the $98.814 million consensus estimate, and said the outlook implies 20% to 26% growth over 2025 excluding Resolve. The company linked its expected tissue-business recovery to post-integration and sales-force restructuring effects following the ExoDx acquisition, adding that recent GPS PROMPT results from the Oxford study and ongoing AI initiatives may help expand market conversion and share gains in active surveillance ahead of the PROTECT study.